Mainz Biomed BV (NASDAQ:MYNZ) — Market Cap & Net Worth
Market Cap & Net Worth: Mainz Biomed BV (MYNZ)
Mainz Biomed BV (NASDAQ:MYNZ) has a market capitalization of $9.49 Million ($9.49 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27143 globally and #5550 in its home market, demonstrating a -16.66% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mainz Biomed BV's stock price $0.76 by its total outstanding shares 12515336 (12.52 Million). Review MYNZ liabilities breakdown to assess the company's total debt and financial obligations.
Mainz Biomed BV Market Cap History: 2021 to 2026
Mainz Biomed BV's market capitalization history from 2021 to 2026. Data shows change from $130.03 Million to $9.49 Million (-55.80% CAGR).
Index Memberships
Mainz Biomed BV is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.00% | #775 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #2509 of 3165 |
Weight: Mainz Biomed BV's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Mainz Biomed BV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mainz Biomed BV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
26.10x
Mainz Biomed BV's market cap is 26.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $130.03 Million | $577.35K | -$11.69 Million | 225.23x | N/A |
| 2022 | $88.86 Million | $529.88K | -$26.45 Million | 167.70x | N/A |
| 2023 | $14.52 Million | $895.48K | -$26.30 Million | 16.21x | N/A |
| 2024 | $54.07 Million | $893.99K | -$21.65 Million | 60.48x | N/A |
| 2025 | $14.02 Million | $537.08K | -$16.21 Million | 26.10x | N/A |
Competitor Companies of MYNZ by Market Capitalization
Companies near Mainz Biomed BV in the global market cap rankings as of August 3, 2026.
Key companies related to Mainz Biomed BV by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #87 globally with a market cap of $215.77 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #169 globally with a market cap of $137.72 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #577 globally with a market cap of $46.48 Billion USD ( CN¥317.64 Billion CNY).
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #616 globally with a market cap of $43.83 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #87 | Thermo Fisher Scientific Inc | NYSE:TMO | $215.77 Billion | $574.30 |
| #169 | Danaher Corporation | NYSE:DHR | $137.72 Billion | $194.98 |
| #577 | WuXi AppTec Co Ltd | SHG:603259 | $46.48 Billion | CN¥128.43 |
| #616 | IDEXX Laboratories Inc | NASDAQ:IDXX | $43.83 Billion | $559.07 |
Mainz Biomed BV Historical Marketcap From 2021 to 2026
Between 2021 and today, Mainz Biomed BV's market cap moved from $130.03 Million to $ 9.49 Million, with a yearly change of -55.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $9.49 Million | -32.29% |
| 2025 | $14.02 Million | -74.07% |
| 2024 | $54.07 Million | +272.41% |
| 2023 | $14.52 Million | -83.66% |
| 2022 | $88.86 Million | -31.67% |
| 2021 | $130.03 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Mainz Biomed BV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.49 Million USD |
| MoneyControl | $9.49 Million USD |
| MarketWatch | $9.49 Million USD |
| marketcap.company | $9.49 Million USD |
| Reuters | $9.49 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Mainz Biomed BV
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes … Read more